Sanofi Acquires Vigil Neuroscience In $470M Deal To Boost Alzheimer’s Drug Development

Sanofi has finalized its acquisition of Vigil Neuroscience, a move aimed at supporting its neurology portfolio. A key asset in this deal is VG-3927, a small-molecule TREM2 agonist currently progressing toward a phase 2 clinical trial for Alzheimer’s disease. Sanofi’s acquisition also brings in Vigil’s broader preclinical pipeline, reinforcing its research capabilities in neurodegenerative disorders. 

This acquisition follows Sanofi’s $40 million strategic investment in Vigil in June 2024, which secured Sanofi an exclusive right of first negotiation for VG-3927. That agreement laid the groundwork for today’s acquisition, which now grants Sanofi full control over the compound’s development, manufacturing, and commercialization rights.

Under the terms, Sanofi is acquiring Vigil for $8 per share, valuing the deal at approximately $470 million. Additionally, Vigil shareholders will receive a $2 contingent value right (CVR) per share, payable upon the first commercial sale of VG-3927. Sanofi did not acquire VGL101, Vigil’s second clinical program. The transaction is not expected to alter Sanofi’s financial forecast for 2025.